Atovaquone

Drug Profile

Atovaquone

Alternative Names: 566C; 566C80; BW 566C; BW A566C; BW A566C80; Mepron; Mepron Suspension; Samtirel; Wellvole; Wellvone

Latest Information Update: 26 Apr 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antiprotozoals; Naphthoquinones
  • Mechanism of Action Electron transport complex I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Pneumocystis pneumonia
  • Discontinued Malaria; Toxoplasmosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 17 Apr 2012 Launched for Pneumocystis pneumonia (treatment and prevention) in Japan (PO; suspension)
  • 18 Jan 2012 Registered for Pneumocystis pneumonia (treatment and prevention) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top